Pfizer Inc (NYSE: PFE), and its partner BioNTech SE (NASDAQ: BNTX), announced positive results for the Phase 1 trial of their second COVID-19 vaccine candidate, stating that the latest vaccine candidate had fewer side effects than their first.What Happened The second vaccine candidate called BNT162b2 or B2 is already in advanced trials and its administration was well tolerated in the trial participants across the age spectrum, according to a statement released by the two companies Thursday. The companies said 332 people participated in the clinical trial, who were administered either the latest vaccine or the first called BNT162b1 or B1.The …read more
Source:: Yahoo Finance
